Michael J. Morris

40.4k total citations · 7 hit papers
463 papers, 18.3k citations indexed

About

Michael J. Morris is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Michael J. Morris has authored 463 papers receiving a total of 18.3k indexed citations (citations by other indexed papers that have themselves been cited), including 361 papers in Pulmonary and Respiratory Medicine, 235 papers in Radiology, Nuclear Medicine and Imaging and 158 papers in Oncology. Recurrent topics in Michael J. Morris's work include Prostate Cancer Treatment and Research (332 papers), Radiopharmaceutical Chemistry and Applications (223 papers) and Prostate Cancer Diagnosis and Treatment (60 papers). Michael J. Morris is often cited by papers focused on Prostate Cancer Treatment and Research (332 papers), Radiopharmaceutical Chemistry and Applications (223 papers) and Prostate Cancer Diagnosis and Treatment (60 papers). Michael J. Morris collaborates with scholars based in United States, Canada and United Kingdom. Michael J. Morris's co-authors include Howard I. Scher, Steven M. Larson, Eric J. Small, Susan Halabi, Tomasz M. Beer, William Kevin Kelly, Glenn Heller, Susan F. Slovin, Karim Fizazi and Celestia S. Higano and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Michael J. Morris

446 papers receiving 18.0k citations

Hit Papers

Design and End Points of Clinical Trials for Patients Wit... 2008 2026 2014 2020 2008 2021 2010 2017 2021 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
    2008 1.7k citations Howard I. Scher, Susan Halabi et al. Journal of Clinical Oncology profile →
  2. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    2021 1.5k citations Oliver Sartor, Johann S. de Bono et al. profile →
  3. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
    2010 809 citations Howard I. Scher, Tomasz M. Beer et al. profile →
  4. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
    2017 507 citations Toni K. Choueiri, Susan Halabi et al. Journal of Clinical Oncology profile →
  5. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18 F-DCFPyL in Prostate Cancer Patients (OSPREY)
    2021 244 citations Kenneth J. Pienta, Michael A. Gorin et al. profile →
  6. Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
    2021 237 citations Michael J. Morris, Steven P. Rowe et al. Clinical Cancer Research profile →
  7. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
    2023 127 citations Robert Seifert, Steven P. Rowe et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael J. Morris United States 65 12.2k 6.9k 5.5k 3.8k 3.3k 463 18.3k
Kathleen R. Lamborn United States 81 5.6k 0.5× 5.7k 0.8× 3.1k 0.6× 5.1k 1.4× 3.1k 0.9× 292 22.7k
Andreas K. Buck Germany 72 4.7k 0.4× 7.6k 1.1× 4.8k 0.9× 2.1k 0.6× 1.7k 0.5× 435 16.9k
Rodney J. Hicks Australia 78 8.5k 0.7× 11.3k 1.6× 7.7k 1.4× 2.0k 0.5× 2.6k 0.8× 602 23.8k
Robert B. Livingston United States 73 8.4k 0.7× 3.0k 0.4× 10.8k 2.0× 3.1k 0.8× 4.5k 1.3× 313 20.7k
Quinn T. Ostrom United States 48 6.4k 0.5× 4.3k 0.6× 3.9k 0.7× 9.3k 2.5× 6.0k 1.8× 154 31.1k
Allan Lipton United States 74 5.0k 0.4× 5.8k 0.8× 15.7k 2.9× 4.8k 1.3× 2.1k 0.6× 411 21.3k
Carol Kruchko United States 47 5.9k 0.5× 3.9k 0.6× 3.6k 0.7× 8.3k 2.2× 5.3k 1.6× 139 29.3k
Mark Rosenthal Australia 40 5.9k 0.5× 1.7k 0.3× 2.7k 0.5× 2.3k 0.6× 1.8k 0.6× 206 10.2k
Kathy D. Miller United States 63 3.9k 0.3× 2.1k 0.3× 9.9k 1.8× 6.0k 1.6× 4.7k 1.4× 331 17.6k
Haley Gittleman United States 33 4.3k 0.4× 2.9k 0.4× 2.9k 0.5× 6.2k 1.6× 4.0k 1.2× 77 21.1k

Countries citing papers authored by Michael J. Morris

Since Specialization
Citations

This map shows the geographic impact of Michael J. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Morris more than expected).

Fields of papers citing papers by Michael J. Morris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Morris. The network helps show where Michael J. Morris may publish in the future.

Co-authorship network of co-authors of Michael J. Morris

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Morris. A scholar is included among the top collaborators of Michael J. Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Morris. Michael J. Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Calais, Jérémie, Michael J. Morris, A. Tuba Kendi, et al.. (2024). Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 65(11). 1666–1671. 5 indexed citations
3.
4.
Imber, Brandon S., Lisa Bodei, John L. Humm, et al.. (2023). A Pilot Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for Oligometastatic Hormone Sensitive Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 117(2). e112–e112. 2 indexed citations
5.
Sumiyoshi, Takayuki, Xiaofei Wang, Evan W. Warner, et al.. (2023). Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. JNCI Journal of the National Cancer Institute. 116(1). 115–126. 2 indexed citations
6.
Danila, Daniel C., Michael J. Morris, Susan F. Slovin, et al.. (2023). Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer. SHILAP Revista de lepidopterología. 6(4). 162–169. 2 indexed citations
7.
Seifert, Robert, Sazan Rasul, Maria Eveslage, et al.. (2023). A Prognostic Risk Score for Prostate Cancer Based on PSMA PET–derived Organ-specific Tumor Volumes. Radiology. 307(4). e222010–e222010. 21 indexed citations
8.
Morris, Michael J., Steven P. Rowe, Michael A. Gorin, et al.. (2021). Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clinical Cancer Research. 27(13). 3674–3682. 237 indexed citations breakdown →
9.
Stopsack, Konrad H., Subhiksha Nandakumar, Andreas G. Wibmer, et al.. (2020). Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clinical Cancer Research. 26(13). 3230–3238. 119 indexed citations
10.
Chakraborty, Goutam, Rahim Hirani, Subhiksha Nandakumar, et al.. (2020). Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2 -altered Prostate Tumors. Clinical Cancer Research. 27(6). 1792–1806. 17 indexed citations
11.
Miyahira, Andrea K., Kenneth J. Pienta, John W. Babich, et al.. (2020). Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. The Prostate. 80(15). 1273–1296. 21 indexed citations
12.
Pérez-López, Raquel, Nina Tunariu, Anwar R. Padhani, et al.. (2019). Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology. 292(2). 273–286. 50 indexed citations
13.
Miyahira, Andrea K., Kenneth J. Pienta, Michael J. Morris, et al.. (2018). Meeting report from the Prostate Cancer Foundation PSMA‐directed radionuclide scientific working group. The Prostate. 78(11). 775–789. 32 indexed citations
14.
Choueiri, Toni K., Susan Halabi, Ben L. Sanford, et al.. (2017). Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology. 35(6). 591–597. 507 indexed citations breakdown →
15.
Beltran, Himisha, Alexander W. Wyatt, Edmund C.P. Chedgy, et al.. (2017). Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical Cancer Research. 23(22). 6802–6811. 52 indexed citations
16.
Morris, Michael J., Dana E. Rathkopf, William Novotny, et al.. (2016). Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 22(15). 3774–3781. 22 indexed citations
17.
Tagawa, Scott T., Matthew I. Milowsky, Michael J. Morris, et al.. (2013). Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 19(18). 5182–5191. 308 indexed citations
18.
Hatzoglou, Vaios, Michael J. Morris, Kristen Curtis, et al.. (2012). Brain Metastases from Prostate Cancer: An 11‐Year Analysis in the MRI Era with Emphasis on Imaging Characteristics, Incidence, and Prognosis. Journal of Neuroimaging. 24(2). 161–166. 69 indexed citations
19.
Danila, Daniel C., Michael J. Morris, Johann S. de Bono, et al.. (2010). Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 28(9). 1496–1501. 318 indexed citations
20.
Osman, Islam, Howard I. Scher, Marija Drobnjak, et al.. (2001). HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.. PubMed. 7(9). 2643–7. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kathleen R. Lamborn Breakdown of academic impact, for papers by Andreas K. Buck Breakdown of academic impact, for papers by Rodney J. Hicks Breakdown of academic impact, for papers by Robert B. Livingston Breakdown of academic impact, for papers by Quinn T. Ostrom Breakdown of academic impact, for papers by Allan Lipton Breakdown of academic impact, for papers by Carol Kruchko Breakdown of academic impact, for papers by Mark Rosenthal Breakdown of academic impact, for papers by Kathy D. Miller Breakdown of academic impact, for papers by Haley Gittleman
Rankless by CCL
2026